Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.16
Nov 20 • 3:59 PM ET Dollar change-0.14 Percentage change(-10.77%)
Aftermarket Close
1.12
Aftermarket • 7:30 PM ET Dollar change-0.04 Percentage change(-3.45%)
Index
-
Market Cap
20.07M
Enterprise Value
18.54M
Income
-148.81M
Sales
0.00M
Book/sh
1.86
Cash/sh
0.27
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
12
IPO
Jul 09, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.62
P/C
4.33
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.96
Current Ratio
0.96
Debt/Eq
0.10
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-54.23
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
96.25% 79.17%
Sales past 3/5Y
- -
EPS Y/Y TTM
77.60%
Sales Y/Y TTM
-
EPS Q/Q
-60.77%
Sales Q/Q
-
Earnings
-
EPS/Sales Surpr.
67.35% -100.00%
Insider Own
5.56%
Insider Trans
0.00%
Inst Own
0.58%
Inst Trans
1.21%
ROA
-581.72%
ROE
-866.08%
ROIC
-452.25%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-22.25%
SMA50
-28.18%
SMA200
-79.02%
Trades
Shs Outstand
17.24M
Shs Float
16.34M
52W High
12.60 -90.79%
52W Low
1.28 -9.38%
Volatility
16.50% 11.13%
ATR (14)
0.17
RSI (14)
28.90
Beta
1.28
Rel Volume
1.17
Avg Volume
52.04K
Volume
60,681
Perf Week
-12.12%
Perf Month
-32.36%
Perf Quarter
-57.04%
Perf Half Y
-81.41%
Perf YTD
-83.02%
Perf Year
-86.45%
Perf 3Y
-99.99%
Perf 5Y
-100.00%
Perf 10Y
-
Prev Close
1.30
Price
1.16
Change %
-10.77%
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. Its lead product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Pharm.Dr. Philippe P. Calais Ph.D.
Scientific Co-Founder & Chief Scientific OfficerDr. Zdravka Medarova Ph.D.
Scientific Co-FounderDr. Anna Moore Ph.D.
Interim Chief Financial OfficerMr. John A. Tattory CPA
Chief Medical OfficerDr. Daniel R. Vlock M.D.